Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000233 · ClinicalTrials.gov registry record · Phase 2

Alternate Day Buprenorphine Administration, Phase X - 15

A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase

NCT00000233: Completed Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

NCT00000233 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000233, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.

Interventions

  • DRUG Buprenorphine

Trial Details

FieldValue
Start Date 1993-05
Phase Phase 2

What the finished NCT00000233 record still lists

NCT00000233 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which Buprenorphine is the first listed.

NCT00000233 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000233 about?

NCT00000233 is a clinical study titled "Alternate Day Buprenorphine Administration, Phase X - 15". The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.

What is the current status of trial NCT00000233?

This trial is currently completed. It is a Phase 2 study. The study started on 1993-05.

What interventions are being tested in trial NCT00000233?

The interventions under investigation include: Buprenorphine (DRUG).

Who is sponsoring clinical trial NCT00000233?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00000233, the US trial registry maintained by the National Library of Medicine. NCT00000233 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.